Key takeaways
Uptravi (selexipag) and Tyvaso (treprostinil) are both medications used to treat pulmonary arterial hypertension (PAH), but they have some key differences. Uptravi is a prostacyclin agonist taken orally as a tablet or through an intravenous (IV) injection, while Tyvaso is a man-made version of prostacyclin, a hormone your body naturally makes. It is available as an inhalation treatment through a nebulizer or dry powdered inhaler (DPI). Uptravi is taken twice a day, whereas Tyvaso needs to be used four times a day. Uptravi can cause side effects like headache, diarrhea, and nausea, while Tyvaso commonly causes cough, headache, and throat irritation. Additionally, Uptravi can cause excess fluid in the lungs, while Tyvaso can cause low blood pressure and increases the risk of bleeding.
